Gilead Sciences (GILD) Revenue (2009 - 2026)

Gilead Sciences (GILD) has reported Revenue for 18 consecutive years, with $7.8 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue rose 10.18% year-over-year to $7.8 billion; the trailing twelve-month figure through Jun 2026 stood at $30.5 billion (up 5.52% YoY), and the FY2025 full-year result was $29.4 billion, up 2.4% from the prior year.
• Revenue grew to $7.8 billion in Q2 2026 per GILD's latest filing, from $7.0 billion in the prior quarter.
• Across five years, Revenue topped out at $7.9 billion in Q4 2025 and bottomed at $6.3 billion in Q2 2022.
• Historically, Revenue has averaged $7.1 billion across 5 years, with a median of $7.0 billion in 2022.
• The sharpest annual moves came in 2022 and 2026: Revenue slipped 5.11% in 2022, then increased 10.18% in 2026.
• Over 5 years, Revenue stood at $7.4 billion in 2022, then decreased by 3.72% to $7.1 billion in 2023, then rose by 6.4% to $7.6 billion in 2024, then increased by 4.7% to $7.9 billion in 2025, then fell by 1.54% to $7.8 billion in 2026.
• According to Business Quant data, Revenue over the past three periods registered $7.8 billion, $7.0 billion, and $7.9 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.